Effect of antipsychotics on spontaneous hyperactivity and hypersensitivity to MK-801-induced hyperactivity in rats prenatally exposed to methylazoxymethanol
Restricted accessResearch articleFirst published online June, 2011
Effect of antipsychotics on spontaneous hyperactivity and hypersensitivity to MK-801-induced hyperactivity in rats prenatally exposed to methylazoxymethanol
Exposure to methylazoxymethanol (MAM) at embryonic day 17 (E17) in the rat has been proposed to be a promising model for schizophrenia that mimics behavioural abnormalities and deficits in prefrontal cortex (PFC) networks. In this study, we investigated for the first time the effects of antipsychotics on abnormal behaviours observed in prenatally MAM-exposed rats. We first examined spontaneous and MK-801-induced locomotor activity in an open field in adult E17 MAM- or saline-exposed rats. Then, the effect of single injections of haloperidol, clozapine and risperidone was investigated in MAM- or sham-exposed rats on spontaneous and MK-801 (0.05 mg/kg)-induced hyperactivity. Risperidone more selectively counteracted the spontaneous hyperactivity in MAM than in sham rats, while haloperidol and clozapine induced similar effects on spontaneous locomotion in both groups. The main result of this study is that all the tested antipsychotics were more effective in attenuating the MK-801-induced hyperlocomotion in MAM than in sham rats. These findings further support the validity of E17 MAM exposure as a model for schizophrenia and add to its heuristic value in screening therapies for schizophrenia.
AdrianiWFeliciASargoliniF (1998) N-methyl-D-aspartate and dopamine receptor involvement in the modulation of locomotor activity and memory processes. Exp Brain Res123(1–2): 52–59.
2.
Al-AminHAWeinbergerDRLipskaBK (2000) Exaggerated MK-801-induced motor hyperactivity in rats with the neonatal lesion of the ventral hippocampus. Behav Pharmacol11(3–4): 269–278.
3.
AnastasioNCJohnsonKM (2008) Atypical anti-schizophrenic drugs prevent changes in cortical N-methyl-D-aspartate receptors and behavior following sub-chronic phencyclidine administration in developing rat pups. Pharmacol Biochem Behav90(4): 569–577.
4.
AndinePWidermarkNAxelssonR (1999) Characterization of MK-801-induced behavior as a putative rat model of psychosis. J Pharmacol Exp Ther290(3): 1393–1408.
5.
ArntJSkarsfeldtT (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology18(2): 63–101.
6.
BaldessariniRJCentorrinoFFloodJGVolpicelliSAHuston-LyonsDCohenBM (1993) Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology9(2): 117–124.
7.
BaldessariniRJHuston-LyonsDCampbellAMarshECohenBM (1992) Do central antiadrenergic actions contribute to the atypical properties of clozapine?Br J Psychiatry160(Suppl 17): 12–16.
8.
BayerSAltmanJ (2004) Development of the telencephalon: neural stem cells, neurogenesis and neuronal migration. In: PaxinosG (ed) The Rat Nervous System, 3rd edn. London: Academic Press, 27–73.
9.
BoksaP (2007) Of rats and schizophrenia. J Psychiatry Neurosci32(1): 8–10.
10.
BramonEWalsheMMcDonaldC (2005) Dermatoglyphics and Schizophrenia: a meta-analysis and investigation of the impact of obstetric complications upon a-b ridge count. Schizophr Res75(2–3): 399–404.
11.
ChartoffEHHeusnerCLPalmiterRD (2005) Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists. Neuropsychopharmacology30(7): 1324–1333.
12.
CookCDNewmanJLWinfreeJCBeardsleyPM (2004) Modulation of the locomotor-activating effects of the noncompetitive NMDA receptor antagonist MK801 by dopamine D2/3 receptor agonists in mice. Pharmacol Biochem Behav77(2): 309–318.
CornishJLNakamuraMKalivasPW (2001) Dopamine-independent locomotion following blockade of N-methyl-D-aspartate receptors in the ventral tegmental area. J Pharmacol Exp Ther298(1): 226–233.
15.
D’SouzaDNHarlanREGarciaMM (2002) Sexually dimorphic effects of morphine and MK-801: sex steroid-dependent and -independent mechanisms. J Appl Physiol92(2): 493–503.
FlagstadPGlenthojBYDidriksenM (2005) Cognitive deficits caused by late gestational disruption of neurogenesis in rats: a preclinical model of schizophrenia. Neuropsychopharmacology30(2): 250–260.
18.
FlagstadPMorkAGlenthojBYvan BeekJMichael-TitusATDidriksenM (2004) Disruption of neurogenesis on gestational day 17 in the rat causes behavioral changes relevant to positive and negative schizophrenia symptoms and alters amphetamine-induced dopamine release in nucleus accumbens. Neuropsychopharmacology29(11): 2052–2064.
19.
FrantzKVan HartesveldtC (1999) Locomotion elicited by MK801 in developing and adult rats: temporal, environmental, and gender effects. Eur J Pharmacol369(2): 145–157.
20.
GattazWFSchummerBBehrensS (1994) Effects of zotepine, haloperidol and clozapine on MK-801-induced stereotypy and locomotion in rats. J Neural Transm Gen Sect96(3): 227–232.
21.
GiovanniniMGRakovskaABentonRSPazzagliMBianchiLPepeuG (2001) Effects of novelty and habituation on acetylcholine, GABA, and glutamate release from the frontal cortex and hippocampus of freely moving rats. Neuroscience106(1): 43–53.
22.
GoffDCCoyleJT (2001) The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry158(9): 1367–1377.
23.
GotoYGraceAA (2006) Alterations in medial prefrontal cortical activity and plasticity in rats with disruption of cortical development. Biol Psychiatry60(11): 1259–1267.
24.
GourevitchRRocherCLe PenGKrebsMOJayTM (2004) Working memory deficits in adult rats after prenatal disruption of neurogenesis. Behav Pharmacol15(4): 287–292.
25.
GramlingSEFowlerSC (1985) Effects of neuroleptics on rate and duration of operant versus reflexive licking in rats. Pharmacol Biochem Behav22(4): 541–545.
26.
Gunduz-BruceH (2008) The acute effects of NMDA antagonism: From the rodent to the human brain. Brain Res Rev 2009;60(2): 279–286.
27.
HaggertyGCBrownG (1996) Neurobehavioral profile of subcutaneously administered MK-801 in the rat. Neurotoxicology17(3–4): 913–921.
28.
HarrisonPJWeinbergerDR (2005) Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry10(1): 40–68.
29.
HauberWAndersenR (1993) The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine. Naunyn Schmiedebergs Arch Pharmacol348(5): 486–490.
30.
HazaneFKrebsMOJayTMLe PenG (2009) Behavioral perturbations after prenatal neurogenesis disturbance in female rat. Neurotoxicity Research15(4): 311–320.
31.
HoareauCHazaneFLe PenGKrebsMO (2006) Postnatal effect of embryonic neurogenesis disturbance on reelin level in organotypic cultures of rat hippocampus. Brain Res1097(1): 43–51.
32.
HonackDLoscherW (1993) Sex differences in NMDA receptor mediated responses in rats. Brain Res620(1): 167–170.
33.
JavittDCZukinSR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry148(10): 1301–1308.
34.
JentschJDRothRH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology20(3): 201–225.
35.
JonesDNCGartlonJEMinassianAPerryWGeyerMA (2008) Developing new drugs for schizophrenia: from animals to the clinic. In: McArthurRBorsiniF (eds) Animal and Translational Models for CNS Drug Discovery: Psychiatric Disorders. New York: Elsevier, 199–262.
36.
Jongen-ReloALLengALuberMPothuizenHHWeberLFeldonJ (2004) The prenatal methylazoxymethanol acetate treatment: a neurodevelopmental animal model for schizophrenia?Behav Brain Res149(2): 159–181.
37.
KemaliDMajMGalderisiSGrazia ArianoMStaraceF (1990) Factors associated with increased noradrenaline levels in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry14(1): 49–59.
38.
KesbyJPBurneTHMcGrathJJEylesDW (2006) Developmental vitamin D deficiency alters MK 801-induced hyperlocomotion in the adult rat: An animal model of schizophrenia. Biol Psychiatry60(6): 591–596.
39.
KrystalJHD’SouzaDCMathalonDPerryEBelgerAHoffmanR (2003) NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl)169(3–4): 215–233.
LavinAMooreHMGraceAA (2005) Prenatal disruption of neocortical development alters prefrontal cortical neuron responses to dopamine in adult rats. Neuropsychopharmacology30(8): 1426–1435.
42.
LawrieSMAbukmeilSS (1998) Brain abnormality in schizophrenia. A systematic and quantitative review of volumetric magnetic resonance imaging studies. Br J Psychiatry172: 110–120.
43.
Le PenGGourevitchRHazaneFHoareauCJayTMKrebsMO (2006) Peri-pubertal maturation after developmental disturbance: a model for psychosis onset in the rat. Neuroscience143(2): 395–405.
44.
LenaIChesselALe PenGKrebsMOGarciaR (2007) Alterations in prefrontal glutamatergic and noradrenergic systems following MK-801 administration in rats prenatally exposed to methylazoxymethanol at gestational day 17. Psychopharmacology (Berl)192(3): 373–383.
45.
LericheLSchwartzJCSokoloffP (2003) The dopamine D3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade. Neuropharmacology45(2): 174–181.
46.
LeuchtSCorvesCArbterDEngelRRLiCDavisJM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet373(9657): 31–41.
47.
LipskaBKWeinbergerDR (2000) To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology23(3): 223–239.
48.
LodgeDJBehrensMMGraceAA (2009) A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia. J Neurosci29(8): 2344–2354.
49.
LodgeDJGraceAA (2007) Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. J Neurosci27(42): 11424–11430.
50.
Lopez-GilXBabotZAmargos-BoschMSunolCArtigasFAdellA (2007) Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology32(10): 2087–2097.
51.
LorrainDSBacceiCSBristowLJAndersonJJVarneyMA (2003) Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience117(3): 697–706.
52.
LubyEDCohenBDRosenbaumGGottliebJSKelleyR (1959) Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry81(3): 363–369.
53.
MalhotraAKPinalsDAAdlerCM (1997) Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology17(3): 141–150.
54.
MatriconJBellonAFrielingH (2010) Neuropathological and Reelin deficiencies in the hippocampal formation of rats exposed to MAM; differences and similarities with schizophrenia. PLoS One5(4): e10291–e10291.
55.
MeleAThomasDNPertA (1998) Different neural mechanisms underlie dizocilpine maleate- and dopamine agonist-induced locomotor activity. Neuroscience82(1): 43–58.
56.
MillanMJLoiseauFDekeyneA (2008) S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects. J Pharmacol Exp Ther324(3): 1212–1226.
57.
MoghaddamBAdamsBVermaADalyD (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci17(8): 2921–2927.
58.
MooreHJentschJDGhajarniaMGeyerMAGraceAA (2006) A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol Psychiatry60(3): 253–264.
O’NeillMFShawG (1999) Comparison of dopamine receptor antagonists on hyperlocomotion induced by cocaine, amphetamine, MK-801 and the dopamine D1 agonist C-APB in mice. Psychopharmacology (Berl)145(3): 237–250.
61.
OlsenCKBrennumLTKreilgaardM (2008) Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics. Eur J Pharmacol584(2–3): 318–327.
62.
OlszewskiRTWegorzewskaMMMonteiroAC (2008) Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors. Biol Psychiatry63(1): 86–91.
63.
OuagazzalAAmalricM (1995) Competitive NMDA receptor antagonists do not produce locomotor hyperactivity by a dopamine-dependent mechanism. Eur J Pharmacol294(1): 137–146.
64.
OwensDG (1996) Adverse effects of antipsychotic agents. Do newer agents offer advantages?Drugs51(6): 895–930.
65.
PenschuckSFlagstadPDidriksenMLeistMMichael-TitusAT (2006) Decrease in parvalbumin-expressing neurons in the hippocampus and increased phencyclidine-induced locomotor activity in the rat methylazoxymethanol (MAM) model of schizophrenia. Eur J Neurosci23(1): 279–284.
66.
PhillipsMWangCJohnsonKM (2001) Pharmacological characterization of locomotor sensitization induced by chronic phencyclidine administration. J Pharmacol Exp Ther296(3): 905–913.
67.
RapoportJLAddingtonAMFrangouSPsychMR (2005) The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry10(5): 434–449.
68.
ScorzaMCMeikleMNHillXLRicheriALorenzoDArtigasF (2008) Prefrontal cortex lesions cause only minor effects on the hyperlocomotion induced by MK-801 and its reversal by clozapine. Int J Neuropsychopharmacol11(4): 519–532.
69.
SidmanRLRakicP (1973) Neuronal migration, with special reference to developing human brain: a review. Brain Res62(1): 1–35.
70.
SimonVMParraAMinarroJArenasMCVinader-CaerolsCAguilarMA (2000) Predicting how equipotent doses of chlorpromazine, haloperidol, sulpiride, raclopride and clozapine reduce locomotor activity in mice. Eur Neuropsychopharmacol10(3): 159–164.
71.
SteinpreisRE (1996) The behavioral and neurochemical effects of phencyclidine in humans and animals: some implications for modeling psychosis. Behav Brain Res74(1–2): 45–55.
72.
StipE (2000) Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics. J Psychiatry Neurosci25(2): 137–153.
73.
SuYASiTMZhouDF (2007) Risperidone attenuates MK-801-induced hyperlocomotion in mice via the blockade of serotonin 5-HT 2A/2C receptors. Eur J Pharmacol564(1–3): 123–130.
74.
SvenssonTH (2000) Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs. Brain Res Brain Res Rev31(2–3): 320–329.
75.
TanHYCallicottJHWeinbergerDR (2007) Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. Cereb Cortex17(Suppl 1): i171–181.
76.
TandonRKeshavanMSNasrallahHA (2008) Schizophrenia, “just the facts” what we know in 2008. 2. Epidemiology and etiology. Schizophr Res102(1–3): 1–18.
77.
van BeijsterveldtLEGeertsRJLeysenJE (1994) Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology (Berl)114(1): 53–62.
78.
Van HornJDMcManusIC (1992) Ventricular enlargement in schizophrenia. A meta-analysis of studies of the ventricle:brain ratio (VBR). Br J Psychiatry160: 687–697.
79.
van KammenDPPetersJvan KammenWB (1989) CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal. Biol Psychiatry26(2): 176–188.
80.
VarvelSAVannREWiseLEPhilibinSDPorterJH (2002) Effects of antipsychotic drugs on operant responding after acute and repeated administration. Psychopharmacology (Berl)160(2): 182–191.
81.
WaddingtonJLLaneALarkinCO’CallaghanE (1999) The neurodevelopmental basis of schizophrenia: clinical clues from cerebro-craniofacial dysmorphogenesis, and the roots of a lifetime trajectory of disease. Biol Psychiatry46(1): 31–39.
82.
WadenbergMLHertelPFernholmRHygge BlakemanKAhleniusSSvenssonTH (2000) Enhancement of antipsychotic-like effects by combined treatment with the alpha1-adrenoceptor antagonist prazosin and the dopamine D2 receptor antagonist raclopride in rats. J Neural Transm107(10): 1229–1238.
83.
WesterinkBHKawaharaYDe BoerP (2001) Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur J Pharmacol412(2): 127–138.
84.
WileyJLMartinBR (2003) Cannabinoid pharmacological properties common to other centrally acting drugs. Eur J Pharmacol471(3): 185–193.
85.
WillinsDLNarayananSWallaceLJUretskyNJ (1993) The role of dopamine and AMPA/kainate receptors in the nucleus accumbens in the hypermotility response to MK801. Pharmacol Biochem Behav46(4): 881–887.
86.
YamamotoKHornykiewiczO (2004) Proposal for a noradrenaline hypothesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry28(5): 913–922.
87.
ZocchiAPertA (1994) Alterations in striatal acetylcholine overflow by cocaine, morphine, and MK-801: relationship to locomotor output. Psychopharmacology (Berl)115(3): 297–304.
